Questcor Pharmaceuticals (QCOR) 83.15 $QCOR
Clinical Trial Results Indicate Acthar May Significantly Reduce Disease Activity in Patients with Systemic Lupus Erythematosus
PR Newswire - Mon May 05, 8:00AM CDT
Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that results from the first modern clinical study examining the use of H.P. Acthar® Gel (repository corticotropin injection) in systemic lupus erythematosus (SLE) has been published in the journal LUPUS. This independent investigator-initiated ten patient study was conducted at Fiechtner Research, a rheumatology research center, and evaluated the efficacy of Acthar in reducing SLE disease activity among patients who presented with moderately to severely active disease despite receiving traditional SLE maintenance treatments. Acthar is approved by the Food and Drug Administration (FDA) for 19 indications, including for use during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus.
Questcor CEO's Daughter Granted Huge Pay Raise
at The Street - Fri May 02, 11:20AM CDT
Her salary jumps to more than $1 million in 2013 from $300,000 in 2012, according to Questcor disclosure.
Awards, Stock Price Updates, Quarterly Earnings Releases, and Clinical Study Results - Analyst Notes on Aetna, Regeneron, Questcor, Medtronic and Lilly
PR Newswire - Thu May 01, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Aetna Inc. (NYSE: AET), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Questcor Pharmaceuticals Inc. (NASDAQ: QCOR), Medtronic Inc. (NYSE: MDT) and Eli Lilly & Co. (NYSE: LLY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1903-100free.
Questcor Pharmaceuticals Up 20.4% Since SmarTrend Uptrend Call (QCOR)
Comtex SmarTrend(R) - Wed Apr 30, 11:05AM CDT
SmarTrend identified an Uptrend for Questcor Pharmaceuticals (NASDAQ:QCOR) on April 1st, 2014 at $67.41. In approximately 4 weeks, Questcor Pharmaceuticals has returned 20.36% as of today's recent price of $81.14.
INVESTOR ALERT - Questcor Pharmaceuticals, Inc.: The Law Offices of Vincent Wong Investigates the Sale of Questcor Pharmaceuticals, Inc. to Mallinckrodt
Business Wire - Wed Apr 30, 10:55AM CDT
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Questcor Pharmaceuticals Inc. (NasdaqGS: QCOR) ("Questcor"
in connection with the sale of the Company to Mallinckrodt.
Small-Cap Growth Stocks: On a Roll With Room to Run
Selena Maranjian, The Motley Fool - Motley Fool - Tue Apr 29, 4:17PM CDT
Exchange-traded funds offer a convenient way to invest in sectors or niches that interest you. If you'd like to add some small-cap growth stocks to your portfolio but don't have the time or expertise to hand-pick a few, the Vanguard Russell 2000...
Questcor Misses on Earnings & Revs in Q1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 10:40AM CDT
Questcor Pharmaceuticals reported first quarter 2014 earnings per share of $1.24, up from the year-ago earnings of $0.85 per share but missed the Zacks Consensus Estimate of $1.71.
QUESTCOR (QCOR) SHAREHOLDER ALERT - The Law firm of Andrews & Springer LLC Announces An Investigation of Questcor Pharmaceuticals, Inc.
PR Newswire - Mon Apr 28, 6:30PM CDT
Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential breach of fiduciary duty claims against the Board of Directors of Questcor Pharmaceuticals, Inc. ("Questcor" or the "Company" (NASDAQ: QCOR) relating to the sale of the Company to Mallinckrodt plc (NYSE: MNK) ("Mallinckrodt" . On April 7, 2014, the two companies announced the signing of a definitive merger agreement pursuant to which Mallinckrodt will acquire Questcor in a merger valued at roughly $5.6 billion. As a result of the merger, shareholders are anticipated to receive $30 in cash and .897 shares of Mallinckrodt for each share of Questcor stock.
Questcor Pharmaceuticals Set to Possibly Rebound After Yesterday's Selloff of 3.01%
Comtex SmarTrend(R) - Mon Apr 28, 4:32PM CDT
Questcor Pharmaceuticals (NASDAQ:QCOR) traded in a range yesterday that spanned from a low of $76.35 to a high of $82.53. Yesterday, the shares fell 3.0%, which took the trading range below the 3-day low of $76.75 on volume of 4.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Growth in Acthar Gel Pushes Questcor's Profits Up by 84% in Q1
Sean Williams, The Motley Fool - Motley Fool - Mon Apr 28, 4:28PM CDT
It was just business as usual for Questcor Pharmaceuticals which delivered another quarter of phenomenal revenue and profit growth to begin 2014. For the first quarter, Questcor reported revenue of $227.1 million, a 68% increase from the...
Questcor Reports First Quarter Financial Results
PR Newswire - Mon Apr 28, 3:01PM CDT
Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today reported financial results for the first quarter ended March 31, 2014.
Cytokinetics' Tirasemtiv Misses Primary Endpoint - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 28, 2:22PM CDT
Shares of Cytokinetics tumbled 64.7% after it announced that tirasemtiv failed to meet its primary endpoint in the phase IIb, BENEFIT-ALS study.
Stocks Stage Late Comeback; Apple Bucks Weakness
at Investor's Business Daily - Mon Apr 28, 1:59PM CDT
Stocks pushed off their session lows and were again mixed in late trading Monday. The Dow Jones industrial average climbed back into positive territory, rising 0.1%. Meanwhile, the Nasdaq was off by 0.7%, and the S&P 500 slipped 0.2%. They were off...
In Line Q3 Loss at ImmunoGen - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 28, 9:40AM CDT
ImmunoGen (IMGN) reported third quarter fiscal 2014 loss of 29 cents per share at par with the Zacks Consensus Estimate.
Stock Futures Higher, Steady: Pfizer Pursuit Lifts Astrazenca
at Investor's Business Daily - Mon Apr 28, 8:00AM CDT
Stock futures put in a strong advance ahead of Monday's open, as investors eyed a rebound after Friday's sharp sell-off. Dow futures were steady, 86.5 points above fair market value. Nasdaq 100 futures were a strong 15 points. S&P 500 futures showed...
Global Acute Respiratory Distress Syndrome Therapeutics Pipeline Review 2014 - Analysis of 9 Companies & 22 Drug Profiles
M2 - Mon Apr 28, 5:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tg98m2/acute_respiratory) has announced the addition of the "Acute Respiratory Distress Syndrome - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Respiratory Distress Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Respiratory Distress Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Acute Respiratory Distress Syndrome - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Acute Respiratory Distress Syndrome and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Acute Respiratory Distress Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Acute Respiratory Distress Syndrome pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Questcor Pharmaceuticals, Inc. - GlaxoSmithKline plc - Phylogica Limited - Altor BioScience Corporation - Therametrics holding AG - Northern Therapeutics, Inc. - Faron Pharmaceuticals Oy - Clarassance, Inc. - Serendex Pharmaceuticals A/S Drug Profiles - interferon beta-1a - dilmapimod - ALT-836 - perfluorocarbon - DasKloster-1000-04 - DasKloster-014101 - drotrecogin alfa (activated) - corticotropin - interferon beta-1a - CG-367 - Gene Therapy For ARDS - Drug to Inhibit Leptin Receptor for Respiratory Disorders - Stromal Cell Therapy For Acute Respiratory Distress Syndrome - Monoclonal Antibody to Inhibit uPA for Acute Lung Injury and Acute Respiratory Distress Syndrome - Drug Inhibiting IGF-1R for Respiratory diseases - PYC-35 - S-1229 - PYC-36 - PYC-38 - PYC-98 - Small Molecules to Inhibit MMP and Cytokine for Immunology, Respiratory and Musculoskeletal Disorders - Human Plasma Protein For more information visit http://www.researchandmarkets.com/research/tg...espiratory
Global Migraine Therapeutics Pipeline Review 2014 - Analysis of 40 Companies & 59 Drug Profiles
M2 - Mon Apr 28, 3:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rw5qnf/migraine) has announced the addition of the "Migraine - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Migraine, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Migraine and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Migraine - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Migraine and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Migraine products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved in Therapeutics Development (Partial List) - Bristol-Myers Squibb Company - Allergan, Inc. - Amgen Inc. - Eli Lilly and Company - Questcor Pharmaceuticals, Inc. - BioDelivery Sciences International, Inc. - Nektar Therapeutics - Merck & Co., Inc. - TheraJect, Inc. - Biofrontera AG - Astellas Pharma Inc. - Dr. Reddy's Laboratories Limited - Pfizer Inc. - Impax Laboratories, Inc. - Revance Therapeutics, Inc. - IntelGenx Corp. - NovaDel Pharma, Inc. - Paladin Labs Inc. - Transcept Pharmaceuticals, Inc. - Pozen, Inc. - D-Pharm Ltd. - Ache Laboratorios Farmaceuticos S/A - Alder Biopharmaceuticals Inc. - CoLucid Pharmaceuticals, Inc. - Charleston Laboratories, Inc. - Pantarhei Bioscience BV - Indus Biotech Private Limited - NeurAxon, Inc. - Noxxon Pharma AG - Monosol Rx, LLC For more information visit http://www.researchandmarkets.com/research/rw5qnf/migraine
Synergy Pharmaceuticals (SGYP) Jumps: Stock Up 10.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 25, 8:39AM CDT
Synergy Pharmaceuticals, Inc. (SGYP) was a big mover last session, as its shares rose nearly 11% on the day.
Product Clearance, Appointments, Upcoming Financial Results, and Clinical Study Results - Analyst Notes on Covidien, Medivation, United Therapeutics, Questcor and CareFusion
PR Newswire - Fri Apr 25, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Covidien plc (NYSE: COV), Medivation, Inc. (NASDAQ: MDVN), United Therapeutics Corporation (NASDAQ: UTHR), Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) and CareFusion Corporation (NYSE: CFN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1611-100free.
OncoGenex Gains Fast Track Status for Custirsen - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 5:50PM CDT
FDA granted Fast Track status to OncoGenex Pharmaceuticals, Inc.'s (OGXI) oncology candidate, custirsen
Clinical Trial Results Indicate Acthar May Significantly Reduce Disease Activity in Patients with Systemic Lupus Erythematosus
PR Newswire - Mon May 05, 8:00AM CDT
Questcor Pharmaceuticals, Inc. (Nasdaq: QCOR) today announced that results from the first modern clinical study examining the use of H.P. Acthar® Gel (repository corticotropin injection) in systemic lupus erythematosus (SLE) has been published in the journal LUPUS. This independent investigator-initiated ten patient study was conducted at Fiechtner Research, a rheumatology research center, and evaluated the efficacy of Acthar in reducing SLE disease activity among patients who presented with moderately to severely active disease despite receiving traditional SLE maintenance treatments. Acthar is approved by the Food and Drug Administration (FDA) for 19 indications, including for use during an exacerbation or as maintenance therapy in selected cases of systemic lupus erythematosus.
Questcor CEO's Daughter Granted Huge Pay Raise
at The Street - Fri May 02, 11:20AM CDT
Her salary jumps to more than $1 million in 2013 from $300,000 in 2012, according to Questcor disclosure.
Awards, Stock Price Updates, Quarterly Earnings Releases, and Clinical Study Results - Analyst Notes on Aetna, Regeneron, Questcor, Medtronic and Lilly
PR Newswire - Thu May 01, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Aetna Inc. (NYSE: AET), Regeneron Pharmaceuticals Inc. (NASDAQ: REGN), Questcor Pharmaceuticals Inc. (NASDAQ: QCOR), Medtronic Inc. (NYSE: MDT) and Eli Lilly & Co. (NYSE: LLY). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1903-100free.
Questcor Pharmaceuticals Up 20.4% Since SmarTrend Uptrend Call (QCOR)
Comtex SmarTrend(R) - Wed Apr 30, 11:05AM CDT
SmarTrend identified an Uptrend for Questcor Pharmaceuticals (NASDAQ:QCOR) on April 1st, 2014 at $67.41. In approximately 4 weeks, Questcor Pharmaceuticals has returned 20.36% as of today's recent price of $81.14.
INVESTOR ALERT - Questcor Pharmaceuticals, Inc.: The Law Offices of Vincent Wong Investigates the Sale of Questcor Pharmaceuticals, Inc. to Mallinckrodt
Business Wire - Wed Apr 30, 10:55AM CDT
The Law Offices of Vincent Wong are investigating potential claims against the Board of Directors of Questcor Pharmaceuticals Inc. (NasdaqGS: QCOR) ("Questcor"
in connection with the sale of the Company to Mallinckrodt. Small-Cap Growth Stocks: On a Roll With Room to Run
Selena Maranjian, The Motley Fool - Motley Fool - Tue Apr 29, 4:17PM CDT
Exchange-traded funds offer a convenient way to invest in sectors or niches that interest you. If you'd like to add some small-cap growth stocks to your portfolio but don't have the time or expertise to hand-pick a few, the Vanguard Russell 2000...
Questcor Misses on Earnings & Revs in Q1 - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Apr 29, 10:40AM CDT
Questcor Pharmaceuticals reported first quarter 2014 earnings per share of $1.24, up from the year-ago earnings of $0.85 per share but missed the Zacks Consensus Estimate of $1.71.
QUESTCOR (QCOR) SHAREHOLDER ALERT - The Law firm of Andrews & Springer LLC Announces An Investigation of Questcor Pharmaceuticals, Inc.
PR Newswire - Mon Apr 28, 6:30PM CDT
Andrews & Springer LLC, a boutique securities class action law firm focused on representing shareholders nationwide, is investigating potential breach of fiduciary duty claims against the Board of Directors of Questcor Pharmaceuticals, Inc. ("Questcor" or the "Company"
(NASDAQ: QCOR) relating to the sale of the Company to Mallinckrodt plc (NYSE: MNK) ("Mallinckrodt" . On April 7, 2014, the two companies announced the signing of a definitive merger agreement pursuant to which Mallinckrodt will acquire Questcor in a merger valued at roughly $5.6 billion. As a result of the merger, shareholders are anticipated to receive $30 in cash and .897 shares of Mallinckrodt for each share of Questcor stock. Questcor Pharmaceuticals Set to Possibly Rebound After Yesterday's Selloff of 3.01%
Comtex SmarTrend(R) - Mon Apr 28, 4:32PM CDT
Questcor Pharmaceuticals (NASDAQ:QCOR) traded in a range yesterday that spanned from a low of $76.35 to a high of $82.53. Yesterday, the shares fell 3.0%, which took the trading range below the 3-day low of $76.75 on volume of 4.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
Growth in Acthar Gel Pushes Questcor's Profits Up by 84% in Q1
Sean Williams, The Motley Fool - Motley Fool - Mon Apr 28, 4:28PM CDT
It was just business as usual for Questcor Pharmaceuticals which delivered another quarter of phenomenal revenue and profit growth to begin 2014. For the first quarter, Questcor reported revenue of $227.1 million, a 68% increase from the...
Questcor Reports First Quarter Financial Results
PR Newswire - Mon Apr 28, 3:01PM CDT
Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) today reported financial results for the first quarter ended March 31, 2014.
Cytokinetics' Tirasemtiv Misses Primary Endpoint - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 28, 2:22PM CDT
Shares of Cytokinetics tumbled 64.7% after it announced that tirasemtiv failed to meet its primary endpoint in the phase IIb, BENEFIT-ALS study.
Stocks Stage Late Comeback; Apple Bucks Weakness
at Investor's Business Daily - Mon Apr 28, 1:59PM CDT
Stocks pushed off their session lows and were again mixed in late trading Monday. The Dow Jones industrial average climbed back into positive territory, rising 0.1%. Meanwhile, the Nasdaq was off by 0.7%, and the S&P 500 slipped 0.2%. They were off...
In Line Q3 Loss at ImmunoGen - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Mon Apr 28, 9:40AM CDT
ImmunoGen (IMGN) reported third quarter fiscal 2014 loss of 29 cents per share at par with the Zacks Consensus Estimate.
Stock Futures Higher, Steady: Pfizer Pursuit Lifts Astrazenca
at Investor's Business Daily - Mon Apr 28, 8:00AM CDT
Stock futures put in a strong advance ahead of Monday's open, as investors eyed a rebound after Friday's sharp sell-off. Dow futures were steady, 86.5 points above fair market value. Nasdaq 100 futures were a strong 15 points. S&P 500 futures showed...
Global Acute Respiratory Distress Syndrome Therapeutics Pipeline Review 2014 - Analysis of 9 Companies & 22 Drug Profiles
M2 - Mon Apr 28, 5:37AM CDT
Research and Markets (http://www.researchandmarkets.com/research/tg98m2/acute_respiratory) has announced the addition of the "Acute Respiratory Distress Syndrome - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Acute Respiratory Distress Syndrome, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Acute Respiratory Distress Syndrome and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Acute Respiratory Distress Syndrome - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Acute Respiratory Distress Syndrome and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Acute Respiratory Distress Syndrome products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Acute Respiratory Distress Syndrome pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Companies Involved in Therapeutics Development - Questcor Pharmaceuticals, Inc. - GlaxoSmithKline plc - Phylogica Limited - Altor BioScience Corporation - Therametrics holding AG - Northern Therapeutics, Inc. - Faron Pharmaceuticals Oy - Clarassance, Inc. - Serendex Pharmaceuticals A/S Drug Profiles - interferon beta-1a - dilmapimod - ALT-836 - perfluorocarbon - DasKloster-1000-04 - DasKloster-014101 - drotrecogin alfa (activated) - corticotropin - interferon beta-1a - CG-367 - Gene Therapy For ARDS - Drug to Inhibit Leptin Receptor for Respiratory Disorders - Stromal Cell Therapy For Acute Respiratory Distress Syndrome - Monoclonal Antibody to Inhibit uPA for Acute Lung Injury and Acute Respiratory Distress Syndrome - Drug Inhibiting IGF-1R for Respiratory diseases - PYC-35 - S-1229 - PYC-36 - PYC-38 - PYC-98 - Small Molecules to Inhibit MMP and Cytokine for Immunology, Respiratory and Musculoskeletal Disorders - Human Plasma Protein For more information visit http://www.researchandmarkets.com/research/tg...espiratory
Global Migraine Therapeutics Pipeline Review 2014 - Analysis of 40 Companies & 59 Drug Profiles
M2 - Mon Apr 28, 3:51AM CDT
Research and Markets (http://www.researchandmarkets.com/research/rw5qnf/migraine) has announced the addition of the "Migraine - Pipeline Review, H1 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Migraine, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Migraine and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Scope - The report provides a snapshot of the global therapeutic landscape of Migraine - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved in the therapeutics development for Migraine and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Migraine products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages Companies Involved in Therapeutics Development (Partial List) - Bristol-Myers Squibb Company - Allergan, Inc. - Amgen Inc. - Eli Lilly and Company - Questcor Pharmaceuticals, Inc. - BioDelivery Sciences International, Inc. - Nektar Therapeutics - Merck & Co., Inc. - TheraJect, Inc. - Biofrontera AG - Astellas Pharma Inc. - Dr. Reddy's Laboratories Limited - Pfizer Inc. - Impax Laboratories, Inc. - Revance Therapeutics, Inc. - IntelGenx Corp. - NovaDel Pharma, Inc. - Paladin Labs Inc. - Transcept Pharmaceuticals, Inc. - Pozen, Inc. - D-Pharm Ltd. - Ache Laboratorios Farmaceuticos S/A - Alder Biopharmaceuticals Inc. - CoLucid Pharmaceuticals, Inc. - Charleston Laboratories, Inc. - Pantarhei Bioscience BV - Indus Biotech Private Limited - NeurAxon, Inc. - Noxxon Pharma AG - Monosol Rx, LLC For more information visit http://www.researchandmarkets.com/research/rw5qnf/migraine
Synergy Pharmaceuticals (SGYP) Jumps: Stock Up 10.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 25, 8:39AM CDT
Synergy Pharmaceuticals, Inc. (SGYP) was a big mover last session, as its shares rose nearly 11% on the day.
Product Clearance, Appointments, Upcoming Financial Results, and Clinical Study Results - Analyst Notes on Covidien, Medivation, United Therapeutics, Questcor and CareFusion
PR Newswire - Fri Apr 25, 7:00AM CDT
Today, Analysts Review released its analysts' notes regarding Covidien plc (NYSE: COV), Medivation, Inc. (NASDAQ: MDVN), United Therapeutics Corporation (NASDAQ: UTHR), Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR) and CareFusion Corporation (NYSE: CFN). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.analystsreview.com/1611-100free.
OncoGenex Gains Fast Track Status for Custirsen - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Apr 24, 5:50PM CDT
FDA granted Fast Track status to OncoGenex Pharmaceuticals, Inc.'s (OGXI) oncology candidate, custirsen
